文献速递甲状腺疾病

甲状腺乳头状癌中微小与肉眼带状肌外侵对复发风险是否存在差异?

Is There a Difference Between Minimal and Gross Extension into the Strap Muscles for the Risk of Recurrence in Papillary Thyroid Carcinomas?
PubMed 文献 · Thyroid · 2020-03-17

本研究分析596例甲状腺乳头状癌(PTC),按外侵程度及其他复发预测因素分组,比较低风险无外侵、中风险无外侵、微小外侵(mETE)和肉眼外侵(gETE)四组的复发风险与治疗反应。结果显示mETE与gETE均为复发的独立危险因素,gETE对复发风险影响更明显且治疗反应更差,mETE可能并非低复发风险,部分患者可能属于中风险,需相应随访。

要点

  • mETE和gETE均为PTC复发的独立危险因素。
  • gETE较mETE对复发风险影响更明显,且治疗反应更差。
  • mETE可能并非低复发风险,部分患者可能属中风险,需相应随访。

核心结论

  • 本研究结果提示mETE和gETE均为PTC复发的独立危险因素。
  • gETE对复发风险影响更明显且与更差治疗反应相关,mETE可能并非与低复发风险相关。
  • 作者认为伴mETE的PTC患者可能部分属于中复发风险,需相应随访。

研究设计与样本

  • 共分析596例PTC,按外侵程度及其他复发预测因素分组。
  • 比较四组:低风险无外侵(n=251)、中风险无外侵(n=89)、mETE(n=191)、gETE(n=65)。
  • 采用Cox比例风险模型分析组间与无病生存期(DFS)的关联。

主要发现

  • 复发风险:低风险无外侵3%,中风险无外侵14%,mETE 14%,gETE 25%。
  • 外侵存在与复发风险升高相关(OR=2.86,95%CI 1.36-5.85,p=0.005),淋巴结转移亦相关(OR=2.44,95%CI 1.25-4.76,p=0.009)。
  • 低风险无外侵患者DFS长于mETE患者(HR=0.08,95%CI 0.02-0.28,p<0.001),但中风险无外侵、mETE与gETE之间无显著差异。
  • gETE患者治疗第一年内生化或结构不完全反应率高于mETE(OR=2.68,95%CI 1.31-5.45,p=0.007),末次随访时亦高于mETE(OR=4.35,95%CI 1.99-9.51,p<0.001)。
  • 无淋巴结转移的微小癌亚组分析中,低风险无外侵与mETE组DFS及治疗反应无显著差异。

临床怎么用

  • 作者认为伴mETE的PTC患者可能部分属于中复发风险,需相应随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The morbidity of papillary thyroid carcinoma (PTC) is primarily related to locoregional recurrences and distant metastases. The definition of minimal extrathyroidal extension (mETE) has been recently revised. The presence of mETE does not impact mortality and is generally not considered to be a predictor for the risk of recurrence. This study aimed at comparing the risk of recurrence and the response to therapy of PTC with mETE and gross extrathyroidal extension (ETE) into the strap muscles (gETE) with low- and intermediate-risk PTC without ETE (low risk w/o ETE and intermediate risk w/o ETE, respectively) to further characterize the impact of ETE on outcomes. Methods: A total of 596 PTCs were analyzed according to the degree of ETE as well as other predictors of recurrence. Four groups of patients were compared, low risk w/o ETE (n = 251), intermediate risk w/o ETE (n = 89), mETE (n = 191), and gETE (n = 65), to determine the risk of recurrence and the response to treatment. Cox proportional hazards models were used to investigate associations between groups and disease-free survival (DFS). Results: The risk of recurrence was 3% in low risk w/o ETE PTC, 14% in intermediate risk w/o ETE, 14% in mETE, and 25% in gETE. The recurrence risk was increased by the presence of ETE (odds ratio [OR] = 2.86, 95% confidence interval [CI] 1.36-5.85, p = 0.005) and lymph node metastases (OR = 2.44 [95% CI 1.25-4.76], p = 0.009). Patients with low-risk carcinomas w/o ETE experienced longer DFS than those with mETE (hazard ratio = 0.08 [95% CI 0.02-0.28], p < 0.001), but no significant difference was observed between intermediate risk w/o ETE, mETE, and gETE. In terms of the response to therapy, patients with gETE had higher rates of biochemical and/or structural incomplete responses within the first year of treatment (OR = 2.68 [95% CI 1.31-5.45], p = 0.007) and at the final follow-up evaluation (OR = 4.35 [95% CI 1.99-9.51], p < 0.001) compared with those with mETE. An analysis of the subgroups of microcarcinomas without lymph node metastases revealed no significant difference in DFS or the response to therapy between the low risk w/o ETE and mETE PTC groups. Conclusions: The results of this study suggest that both mETE and gETE are independent risk factors for the risk of recurrence in PTC. Although gETE has a more pronounced impact on the recurrence risk and is associated with a worse response to therapy, mETE may not be associated with a low risk of recurrence. This observation suggests that patients with PTC and mETE may, in part, have an intermediate risk of recurrence and need to be followed accordingly.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Danilovic DLS, Castroneves LA, Suemoto CK, et al. Is There a Difference Between Minimal and Gross Extension into the Strap Muscles for the Risk of Recurrence in Papillary Thyroid Carcinomas? Thyroid. 2020. PMID: 32059626. doi:10.1089/thy.2019.0753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。